To encourage clinicians and researchers based in Europe to increase insight into immune thrombocytopenia (ITP) or to improve knowledge of the Spleen Tyrosine Kinase (SYK) inhibition as mechanism of action.


The award provides 1 grant of 50,000 EUR to the participant whose proposal best matches the program's objectives as assessed by an independent Review Committee. Funding is intended to support a 18-month project.


The proposals submitted by the participants are evaluated based on four criteria:

  • Scientific merit
  • Innovation
  • Clinical / medical impact
  • Quality of research environment


Scientists or clinicians with an innovative idea in the field of immune thrombocytopenia (ITP) or related to the Spleen Tyrosine Kinase (SYK) inhibition as mechanism of action, are invited to apply. Applications are encouraged from both individuals and teams who are undertaking research at universities, hospitals or independent research institutions in Europe.


Eligible applicants must submit a curriculum vitae (CV) and a Letter of Intent outlining the aims of their research project. Application letters that fulfill the terms of entry will be assessed and judged by the Review Committee comprised of six experts from healthcare and research. Based on their review, the Committee will invite several candidates to submit a full research proposal. The Review Committee will evaluate the research proposals and select the award recipient.